Richard Sear
Managing Partner
Everest Group
Dawid Sierzant
Partner
SDP Sierzant Dudzinski
Mariusz Kondrat
Managing Partner
Kondrat & Partners
Evelina Kurgonaite
Secretary General
Fair Standards Alliance
A multidisciplinary roundtable discussion focusing on the unmet needs and adverse impact of moderate to severe vasomotor symptoms (VMS) due to menopause on women’s health outcomes.
Jamie Grossman, PhD, MBA
National Account Director, Health Economics & Outcomes Research
Bayer
Angie Lee, MD, FACOG
Executive Medical Director, Women’s Health Care
Bayer
Bayer
Website: https://www.bayer.com/en/
Bayer is a recognized leader in the area of women’s healthcare, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide. Today, Bayer’s research and development efforts focus on finding new treatment options for menopause as well as gynecological diseases and includes several compounds in various stages of pre-clinical and clinical development. Together, these projects reflect the company’s approach to research, which prioritizes targets and pathways with the potential to alter the way that gynecological diseases are treated. Additionally, Bayer intends to provide 100 million women in low-and-middle income countries by 2030 with access to family planning by funding multi-stakeholder aid programs and by ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations.
